The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6
Menée sur différentes lignées cellulaires de cancers humains, cette étude met en évidence le rôle d'une enzyme de la famille des histones méthyltransférases, JMJD2B, dans la cancérigenèse
Histone methyltransferases and demethylases are known to regulate transcription by altering the epigenetic marks on histones, but the pathological roles of their dysfunction in human diseases like cancer still remain to be elucidated. Herein, we demonstrate that the histone demethylase JMJD2B is involved in human carcinogenesis. Quantitative real-time PCR showed notably elevated levels of JMJD2B expression in bladder cancers compared with corresponding non-neoplastic tissues (P < 0.0001), and elevated protein expression was confirmed by immunohistochemistry. Additionally, cDNA microarray analysis revealed transactivation of JMJD2B in lung cancer, and immunohistochemical analysis showed protein overexpression in lung cancer. siRNA-mediated reduction of expression of JMJD2B in bladder and lung cancer cell lines significantly suppressed the proliferation of cancer cells, and suppressing JMJD2B expression lead to a decreased population of cancer cells in S phase, with a concomitant increase of cells in G1 phase. Furthermore, a clonogenicity assay showed that the demethylase activity of JMJD2B possesses an oncogenic activity. Microarray analysis after knockdown of JMJD2B revealed that JMJD2B could regulate multiple pathways which contribute to carcinogenesis, including the cell cycle pathway. Of the downstream genes, chromatin immunoprecipitation demonstrated that CDK6 (cyclin-dependent kinase 6), essential in G1/S transition, was directly regulated by JMJD2B, via demethylation of histone H3-K9 in its promoter region. Expression levels of JMJD2B and CDK6 were significantly correlated in various types of cell lines. Deregulation of histone demethylation resulting in perturbation of the cell cycle, represents a novel mechanism for human carcinogenesis and JMJD2B is a feasible molecular target for anti-cancer therapy.